On 26 February 2019, orphan designation (EU/3/19/2138) was granted by the European Commission to Common Services Agency (National Health Services - Scotland), United Kingdom, for allogeneic anti-Epstein Barr virus cytotoxic lymphocytes expanded ex vivo for the treatment of post-transplant lymphoproliferative disorder.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in July 2021 on request of the Sponsor.
Allogeneic anti-Epstein Barr virus cytotoxic T lymphocytes expanded ex vivo
Treatment of post-transplant lymphoproliferative disorder
|Orphan designation status||
|EU designation number||
|Date of designation||
Common Services Agency (National Health Services - Scotland)
Documents related to this orphan designation evaluation
EU/3/19/2138: Public summary of opinion on orphan designation: Allogeneic anti-Epstein Barr virus cytotoxic T lymphocytes expanded ex vivo for the treatment of post-transplant lymphoproliferative disorder (PDF/192.32 KB)
First published: 02/10/2019
Last updated: 21/07/2021
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: